- Foundation Medicine (NASDAQ:FMI) announces preliminary total revenue of ~$48.9M for Q4 2017 and ~$152.9M for FY2017, representing a 70% and 31% increase from Q4 2016 and FY2016, respectively.
- Revenue from biopharmaceutical companies is expected to be ~$33.4M in Q4 and ~$99.7M for FY2017.
- Clinical testing revenues of ~$15.5M and ~$53.1M in Q4 and FY2017, respectively.
- Molecular Information Services revenue of ~$37.4M and ~$117.1M in Q4 and FY2017, respectively.
- Pharma R&D Services revenue of ~$11.5M and ~$35.8M in Q4 and FY2017, respectively.
- The company reported 6,206 tests to biopharmaceutical customers and 20,044 clinical tests to ordering physicians in Q4. A total of 67,375 clinical tests were reported for FY2017, an increase of 54% over FY2016.
- The Company will also present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 3:30 p.m. PST, in San Francisco.
- Now read: Alexion Pharmaceuticals (NASDAQ:ALXN): A High Conviction, Large Cap Orphan Disease Pick For 2018
Original article